title: Long-lasting control with erlotinib in advanced non-small cell lung cancer (NSCLC).
abstract: The authors present a clinical case of a caucasian male patient, 59 years-old, non-smoker, with an advanced non-small cell lung carcinoma (NSCLC), with 3 years of follow-up, received erlotinib for 18 months, after failure of more than one chemotherapy schedule, without evidence of oncologic progression. The patient evidences excellent quality of life, controlled sintomatology, recovery of the capacity of tolerance to the effort and it maintains his professional activities. The treatment with erlotinib has been well tolerated, although exhibiting grade 1 cutaneous toxicity. Rev Port Pneumol 2008; XIV (Supl 3): S9-S15.
authors.affiliation: Assistente Hospitalar de Oncologia Médica, Unidade de Oncologia, Hospital Pedro Hispano, EPE, Matosinhos, Portugal; Os dois primeiros autores contribuíram de igual forma para este artigo. Electronic address: teresa.guimaraes@hph.min-saude.pt.
authors.forename: Teresa
authors.initials: T
authors.lastname: Guimarães
authors.affiliation: Interna Complementar de Oncologia Médica, IPO-FG, EPE, Porto, Portugal; Os dois primeiros autores contribuíram de igual forma para este artigo.
authors.forename: Ana
authors.initials: A
authors.lastname: Castro
authors.affiliation: Assistente Hospitalar de Pneumologia, Unidade de Pneumologia, Hospital Pedro Hispano, EPE, Matosinhos, Portugal.
authors.forename: Nuno
authors.initials: N
authors.lastname: Cortesão
authors.affiliation: Assistente Graduado de Pneumologia, Unidade de Pneumologia, Hospital Pedro Hispano, EPE, Matosinhos, Portugal.
authors.forename: Jorge
authors.initials: J
authors.lastname: Ferreira
authors.affiliation: Chefe Serviço e Directora da Unidade de Pneumologia, Hospital Pedro Hispano, EPE, Matosinhos, Portugal.
authors.forename: Fernanda
authors.initials: F
authors.lastname: João
keywords: CPNPC; Carcinoma do pulmão de não pequenas células avançado ou metastático; Locally advanced or metastatic non-small cell lung cancer; NSCLC; chemotherapy; erlotinib; inibi-dores da tirosina quinase (HER1/EGFR); quimioterapia; thyrosine kinase epidermal growth factor receptor inhibitor (HER1/ EGFR)